The Long Wait for a New Drug for Human African Trypanosomiasis
- PMID: 30181071
- DOI: 10.1016/j.pt.2018.08.006
The Long Wait for a New Drug for Human African Trypanosomiasis
Abstract
Human African trypanosomiasis (HAT) is responsible for around 3000 reported cases each year. Treatments for HAT are expensive and problematic to administer, and available drugs are old and less than ideal, some with high levels of toxicity that result in debilitating and, in some cases, fatal side effects. Treatment options are limited, with only one drug, eflornithine, introduced in the last 28 years. Here we examine the limitations of current chemotherapeutic approaches to manage HAT, the constraints to new drug development exploring drug failures and new drugs on the horizon, and consider the epidemiological, political, social, and economic factors influencing drug development.
Keywords: T. b. gambiense (g-HAT); T. b. rhodesiense (r-HAT); drug discovery; human African trypanosomiasis (HAT); sleeping sickness; tsetse.
Copyright © 2018. Published by Elsevier Ltd.
Similar articles
-
Impact of mass chemotherapy in domestic livestock for control of zoonotic T. b. rhodesiense human African trypanosomiasis in Eastern Uganda.Acta Trop. 2017 Jan;165:216-229. doi: 10.1016/j.actatropica.2016.08.022. Epub 2016 Aug 25. Acta Trop. 2017. PMID: 27570206
-
Evaluating the impact of targeting livestock for the prevention of human and animal trypanosomiasis, at village level, in districts newly affected with T. b. rhodesiense in Uganda.Infect Dis Poverty. 2017 Feb 6;6(1):16. doi: 10.1186/s40249-016-0224-8. Infect Dis Poverty. 2017. PMID: 28162093 Free PMC article.
-
Chemotherapy against human African trypanosomiasis: is there a road to success?Parasitology. 2010 Dec;137(14):1987-94. doi: 10.1017/S0031182010001137. Epub 2010 Oct 20. Parasitology. 2010. PMID: 20961469 Review.
-
Current chemotherapy of human African trypanosomiasis.Parasitol Res. 2003 Jun;90 Supp 1:S10-3. doi: 10.1007/s00436-002-0752-y. Epub 2002 Nov 23. Parasitol Res. 2003. PMID: 12811544 Review.
-
Delivery of antihuman African trypanosomiasis drugs across the blood-brain and blood-CSF barriers.Adv Pharmacol. 2014;71:245-75. doi: 10.1016/bs.apha.2014.06.003. Epub 2014 Aug 22. Adv Pharmacol. 2014. PMID: 25307219 Review.
Cited by
-
Quinolone scaffolds as potential drug candidates against infectious microbes: a review.Mol Divers. 2024 Apr 29. doi: 10.1007/s11030-024-10862-4. Online ahead of print. Mol Divers. 2024. PMID: 38683488 Review.
-
Lead Optimization of the 5-Phenylpyrazolopyrimidinone NPD-2975 toward Compounds with Improved Antitrypanosomal Efficacy.J Med Chem. 2024 Feb 22;67(4):2849-2863. doi: 10.1021/acs.jmedchem.3c01976. Epub 2024 Feb 8. J Med Chem. 2024. PMID: 38330051 Free PMC article.
-
Targeting RNA Structure to Inhibit Editing in Trypanosomes.Int J Mol Sci. 2023 Jun 14;24(12):10110. doi: 10.3390/ijms241210110. Int J Mol Sci. 2023. PMID: 37373258 Free PMC article.
-
A structure-based virtual high-throughput screening, molecular docking, molecular dynamics and MM/PBSA study identified novel putative drug-like dual inhibitors of trypanosomal cruzain and rhodesain cysteine proteases.Mol Divers. 2024 Apr;28(2):531-551. doi: 10.1007/s11030-023-10600-2. Epub 2023 Jan 8. Mol Divers. 2024. PMID: 36617352
-
Systematic Review and Meta-Analysis on Human African Trypanocide Resistance.Pathogens. 2022 Sep 25;11(10):1100. doi: 10.3390/pathogens11101100. Pathogens. 2022. PMID: 36297157 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources